Role of Difucosylated Lewis Y Antigen in Outcome of Locally Advanced Cervical Squamous Cell Carcinoma Treated with Cisplatin Regimen
| Autor: | Julian Iturbe, Carlos Teodoro Vallejo, Bernardo Amadeo Leone, Jose Pablo Leone, G. Grosman, Maria C. Mac Donnell, J E Perez, Julieta Leone, Maria Ester Dominguez, Ariel Osvaldo Zwenger |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
0301 basic medicine Oncology Cancer Research medicine.medical_specialty Cervical Squamous Cell Carcinoma Clinical Biochemistry Locally advanced Uterine Cervical Neoplasms Antineoplastic Agents Pathology and Forensic Medicine 03 medical and health sciences Lewis Blood Group Antigens 0302 clinical medicine Internal medicine Humans Medicine Neoplasm Staging Cervical cancer Cisplatin Lewis Y antigen biology business.industry CD44 medicine.disease Regimen 030104 developmental biology 030220 oncology & carcinogenesis Carcinoma Squamous Cell biology.protein Female business medicine.drug |
| Zdroj: | The International Journal of Biological Markers. 31:300-308 |
| ISSN: | 1724-6008 |
| DOI: | 10.5301/jbm.5000206 |
| Popis: | Background Several mechanisms are involved in the development of resistance to therapy in locally advanced cervical squamous cell carcinoma (LACSCC). Studies have shown that CD44 and Lewis Y antigen (LeY) form a complex that is associated with chemoresistance, tumor invasion and metastasis. We assessed the role of CD44 and LeY in the outcome of LACSCC patients treated with different chemotherapy regimens. Methods 126 LACSCC patients at FIGO stages IIB-IVA were selected from the GOCS database: 74 patients included in 3 different prospective phase II trials in the neoadjuvant setting (vinorelbine, docetaxel, ifosfamide-vinorelbine-cisplatin) and 52 patients treated with standard radiochemotherapy based on cisplatin (RCBC). Clinical data at baseline, disease-free survival (DFS) and overall survival (OS) were recorded. Univariate and multivariate Cox models were employed. Results Median age was 45.6 years (range: 24.9-80.5). Sixty-three and 47 tumors were CD44+ and LeY+, respectively. Tumors with expansive growth showed higher grade (p = 0.0024), mitotic index (p = 0.0505), tumor necrosis (p = 0.0191), LeY+ (p = 0.0034) and CD44+/LeY+ coexpression (p = 0.0334). CD44+ cells were present in 91.3% of patients with local recurrence (p = 0.0317). Advanced stage was associated with LeY+ tumors. Patients treated with RCBC had worse DFS and OS when their tumors expressed LeY (p = 0.0083 and p = 0.0137, respectively). Pre-treatment hemoglobin level, FIGO stage and tumor response remained the most significant prognostic factors in Cox regression. Conclusions In our cohort of LACSCC patients, the coexpression of CD44 and LeY was not associated with worse outcome. However, in the subgroup of patients receiving RCBC, LeY expression was correlated with shorter DFS and OS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|